These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9545113)

  • 1. Persistently increased gastrin and decreased pepsinogen concentrations in serum from some patients with Graves' disease of triiodothyronine-predominant type and common type.
    Fukao A; Takamatsu J; Shimamoto C; Kuma K; Ohsawa N
    Thyroid; 1998 Mar; 8(3):259-63. PubMed ID: 9545113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial hyperplasia and decreased colloid content of the thyroid gland in triiodothyronine-predominant Graves' disease.
    Takamatsu J; Takeda K; Katayama S; Sakane S; Morita S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1145-50. PubMed ID: 1400885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
    Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
    J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J; Sugawara M; Kuma K; Kobayashi A; Matsuzuka F; Mozai T; Hershman JM
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma free triiodothyronine response to thyrotropin-releasing hormone to predict the remission of Graves' disease treated with antithyroid drugs.
    Notsu K; Oka N; Masaki Y; Furuya H; Kato Y
    J Clin Endocrinol Metab; 1991 Aug; 73(2):396-400. PubMed ID: 1713218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathological characteristics of the thyroid gland in patients with triiodothyronine-predominant Graves' disease].
    Miki K; Takamatsu J; Sakane S; Majima M; Kitaoka H; Kitazawa A; Mozai T; Katayama S; Morita S; Kobayashi A
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar; 63(3):184-92. PubMed ID: 3609395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
    Takamatsu J; Kuma K; Mozai T
    J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease of immunoglobulin G-Fc receptor-bearing T lymphocytes in Graves' disease.
    Mori H; Amino N; Iwatani Y; Asari S; Izumiguchi Y; Kumahara Y; Miyai K
    J Clin Endocrinol Metab; 1982 Sep; 55(3):399-402. PubMed ID: 6178751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T3-release from autonomously functioning thyroid nodules in vitro.
    Poertl S; Kirner J; Saller B; Mann K; Hoermann R
    Exp Clin Endocrinol Diabetes; 1998; 106(6):489-93. PubMed ID: 10079030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease.
    Wenzel KW; Lente JR
    J Endocrinol Invest; 1983 Oct; 6(5):389-94. PubMed ID: 6141202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3).
    Chopra IJ; Williams DE; Orgiazzi J; Solomon DH
    J Clin Endocrinol Metab; 1975 Nov; 41(5):911-20. PubMed ID: 1242390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.